Get started
Author

Seth Seegobin

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2011 · Javier Cortes, Joyce O'Shaughnessy, et al. · The Lancet · 1,095
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial
2017 · Ruth E. Cooper, Emma Williams, et al. · European Neuropsychopharmacology · 175
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
2021 · Sophie Glatt, Gregor B. E. Jemec, et al. · JAMA Dermatology · 172
PDF
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02
2019 · Christos Tziotzios, Christos Petridis, et al. · Nature Communications · 121
PDF
ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial
2014 · Seth D Seegobin, Margaret HY Ma, et al. · Arthritis Research & Therapy · 105
PDF
Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking
2013 · Ian C. Scott, Seth D. Seegobin, et al. · PLoS Genetics · 63
PDF
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer
2014 · Hyman Muss, Javier Cortes, et al. · The Oncologist · 48
PDF
A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.
2010 · C. Twelves, D. Loesch, et al. · Journal of Clinical Oncology · 40
Validation of the standardised assessment of personality - abbreviated scale in a general population sample
2015 · Marcella Lei-Yee Fok, Seth Seegobin, et al. · Personality and Mental Health · 34
PDF
LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
2021 · Myron J Levin, Andrew Ustianowski, et al. · Open Forum Infectious Diseases · 32
Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen‐presenting cells in skin
2016 · Tania Brocks, Oleg Fedorchenko, et al. · The FASEB Journal · 25
Frontal fibrosing alopecia: there is no statistically significant association with leave-on facial skin care products and sunscreens
2016 · S.D. Seegobin, C. Tziotzios, et al. · British Journal of Dermatology · 21
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 15
PDF
The effect of carbon and nutrient loading during nursery culture on the growth of black spruce seedlings: a six-year field study
2007 · Danielle A. Way, Seth D. Seegobin, et al. · New Forests · 13
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
2023 · Maheshi N Ramasamy, Elizabeth J Kelly, et al. · The Lancet Microbe · 9
PDF
Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane
2010 · C Twelves, D Loesch, et al. · Cancer Research · 8
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
2024 · Sue Ann Costa Clemens, Brett Jepson, et al. · The Lancet Microbe · 7
The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
2011 · C. Twelves, L. T. Vahdat, et al. · Journal of Clinical Oncology · 6
Correction: Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking
2013 · Ian C. Scott, Seth D. Seegobin, et al. · PLoS Genetics · 5
PDF
Basic Science * 208. Stem Cell Factor Expression is Increased in the Skin of Patients with Systemic Sclerosis and Promotes Proliferation and Migration of Fibroblasts in vitro
2013 · S. Karrar, X. Shiwen, et al. · Lara D. Veeken · 5
Abstract P6-13-01: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study
2010 · JL Blum, CJ Twelves, et al. · Cancer Research · 5
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
2023 · Tomas O Jensen, Greg A Grandits, et al. · The Journal of Infectious Diseases · 4
PDF
Abstract P6-13-02: Survival Outcomes with Eribulin Mesylate vs. Treatment of the Physician's Choice (TPC) in Heavily Pretreated Subjects with Locally Recurrent or Metastatic Breast Cancer in North America, Western Europe, and Australia: Results of the Phase III EMBRACE Study
2010 · LT Vahdat, CJ Twelves, et al. · Cancer Research · 3
P-1969. Safety, Immunogenicity, and Pharmacokinetics of Repeat Dosing with AZD7442 (Tixagevimab/Cilgavimab): Final Analysis of the ENDURE Phase 2, Dose-Ranging Study in Immunocompromised Participants
2025 · Taylor Cohen, Marimer Rensoli Valzquez, et al. · Open Forum Infectious Diseases · 2
PDF
Works count: 35
Citation count: 2,082
H-index: 14
I10-index: 15
Year
Topic
Type